We wrote a letter to President Biden & Congress from hundreds of CEOs, investors & academics, urging them to solve affordability for patients through insurance reforms. We CAN save Americans money without destroying the ecosystem that creates new medicines nopatientleftbehind.docsend.com/view/a6bxibzxy… Join us

With rising out-of-pocket healthcare costs, the conversation around drug pricing is as important as ever; however, government dictation of pricing is not the answer. By disincentivizing investment in biotech, we stifle innovation. nopatientleftbehind.docsend.com/view/a6bxibzxy…

Dear Lawmakers President Biden Ron Wyden Nancy Pelosi Hundreds of us biotech investors, innovators, patient advocates, & NIH academics representing >40k US jobs, >600 drugs in trials, & >$200B invested propose solutions to affordability that preserve R&D. 1/ nopatientleftbehind.docsend.com/view/a6bxibzxy…

An important message from the innovators of the healthcare ecosystem, those creating the next generation of medicines. Calling attention for Congressman Raja Krishnamoorthi and others in Congress to please avoid knee jerk reactions that will hurt innovation with no money saving benefit.

I am not typically a joiner, but I was proud to sign this letter.

This letter is the result of collaboration with my fantastic colleagues Soufiane Aboulhouda Sherif Gerges Madalyn Vidisha Mohad Anjali Ramaswamy with inspiration and mentorship from Peter Kolchinsky Aoifemlbrennan Alex Karnal Jeremy Levin Laura Shawver Daphne Zohar No Patient Left Behind

Hey biotweeps -- Webinar coming Feb 10 on building the perfect syndicate, coordinated with our annual list of the top 100 VCs in the #biotech biz. With Michael Gilman , Arjun Goyal, Gary Glick, Laura Shawver and Chris Dokomajilar Round table talk on key topic. webinars.endpts.com/the-top-100-vc…

Making a list of rockstar biotech CEOs that happen to be women. Athena Countouriotis selling $TPTX for $4.1B today, Laura Shawver (Synthorx $2.5B M&A), Kiran Mazumdar-Shaw (proud to have on my BoD built multibillion$ Biocon), Angie You (largest preclin M&A $1B+) Pls reply w/others

We are part of an amazing and important ecosystem that saves lives - and we are in jeopardy! All biotech CEO’s should join in signing this letter!

Laura Shawver And all employees! At this point, it’s not enough to get just a few hundred CEOs to speak. We are all citizens of this ecosystem, we are all patients, too, now or someday, and we must all lend our voice to this message to get Congress to realize these details matter!

Over 1000 people (patients, physicians, academics, innovators, & investors) signed letter urging Senators to consider harms of imposing price controls on small molecules after just 9 years on the market. U can sign 2. SenateHELP Committee please listen & fix. nopatientleftbehind.docsend.com/view/xaxy2n7vp…

I always enjoy my conversations with John Carroll

It's a privilege to do this for a third year now with Bruce Levine, Ph.D. 🇺🇦. We catch up on the latest advances in cell therapy including armored CARs, in-vivo editing, cell Tx for non-oncology indications, and more. #ATW23

Great visit w Capstan Therapeutics innovators today! capstantx.com Laura Shawver wears the "Intern" labcoat on our lab tour 😂

I love this for so many reasons!

Great way to spend a Sunday! SU2Cscience @SU2CScienceSummit

in-vivo CAR-T - will be transformational if works as advertised. (i.e., low cost of goods, no lymphodepletion, potential for outpatient administration) Lots of technical risk on the table remains so let’s not get too excited yet, but this is what moonshot science looks like.